JP2007508326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508326A5 JP2007508326A5 JP2006534467A JP2006534467A JP2007508326A5 JP 2007508326 A5 JP2007508326 A5 JP 2007508326A5 JP 2006534467 A JP2006534467 A JP 2006534467A JP 2006534467 A JP2006534467 A JP 2006534467A JP 2007508326 A5 JP2007508326 A5 JP 2007508326A5
- Authority
- JP
- Japan
- Prior art keywords
- received
- group
- intron
- peg
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 3
- 229940106366 pegintron Drugs 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51073303P | 2003-10-11 | 2003-10-11 | |
| PCT/US2004/033739 WO2005037274A1 (en) | 2003-10-11 | 2004-10-12 | Combination therapy for hcv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508326A JP2007508326A (ja) | 2007-04-05 |
| JP2007508326A5 true JP2007508326A5 (enExample) | 2007-10-11 |
Family
ID=34465143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534467A Pending JP2007508326A (ja) | 2003-10-11 | 2004-10-12 | Ｈｃｖ感染のための組み合わせ治療 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050112093A1 (enExample) |
| EP (1) | EP1670462A1 (enExample) |
| JP (1) | JP2007508326A (enExample) |
| KR (1) | KR20060120037A (enExample) |
| CN (1) | CN1882335A (enExample) |
| AR (1) | AR045870A1 (enExample) |
| AU (1) | AU2004281747A1 (enExample) |
| BR (1) | BRPI0415249A (enExample) |
| CA (1) | CA2541857A1 (enExample) |
| IL (1) | IL174864A0 (enExample) |
| MX (1) | MXPA06004077A (enExample) |
| NO (1) | NO20062104L (enExample) |
| PE (1) | PE20050477A1 (enExample) |
| RU (1) | RU2006115916A (enExample) |
| TW (1) | TW200528104A (enExample) |
| WO (1) | WO2005037274A1 (enExample) |
| ZA (1) | ZA200602912B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US20120201883A1 (en) * | 2004-05-21 | 2012-08-09 | Accu-Break Technologies, Inc | Antiviral compositons |
| MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
| ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| JP2009531315A (ja) | 2006-03-16 | 2009-09-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 重水素化ｃ型肝炎プロテアーゼインヒビター |
| US8575208B2 (en) * | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| FR2928146B1 (fr) * | 2008-02-28 | 2010-02-19 | Saint Gobain Isover | Produit a base de fibres minerales et son procede d'obtention. |
| AU2009293493B2 (en) * | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| EP2396028A2 (en) * | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| WO2011001897A1 (ja) * | 2009-06-30 | 2011-01-06 | 明治製菓株式会社 | 難治性のｃ型慢性肝炎の治療のための薬剤及び方法 |
| US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
| KR20120106942A (ko) | 2009-10-30 | 2012-09-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법 |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| WO2017223178A1 (en) * | 2016-06-21 | 2017-12-28 | Trek Therapeutics, Pbc | Treating viral infections with impdh inhibitors |
| WO2018169283A1 (ko) * | 2017-03-14 | 2018-09-20 | 국립암센터 | C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도 |
| CN109745315B (zh) * | 2019-03-08 | 2021-04-16 | 中国农业科学院兰州兽医研究所 | 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL192628B1 (pl) * | 1996-04-23 | 2006-11-30 | Vertex Pharma | Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji |
| DE69901321T2 (de) * | 1998-05-15 | 2002-12-12 | Schering Corp., Kenilworth | Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind |
| US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
| WO2003101199A1 (en) * | 2002-05-31 | 2003-12-11 | Schering Corporation | Combination therapy for rna virus infections involving ribavirin and impdh inhibitors |
-
2004
- 2004-10-08 AR ARP040103677A patent/AR045870A1/es not_active Application Discontinuation
- 2004-10-11 PE PE2004000979A patent/PE20050477A1/es not_active Application Discontinuation
- 2004-10-11 TW TW093130756A patent/TW200528104A/zh unknown
- 2004-10-12 ZA ZA200602912A patent/ZA200602912B/en unknown
- 2004-10-12 CN CNA2004800335847A patent/CN1882335A/zh active Pending
- 2004-10-12 JP JP2006534467A patent/JP2007508326A/ja active Pending
- 2004-10-12 KR KR1020067006996A patent/KR20060120037A/ko not_active Withdrawn
- 2004-10-12 US US10/964,243 patent/US20050112093A1/en not_active Abandoned
- 2004-10-12 EP EP04794964A patent/EP1670462A1/en not_active Withdrawn
- 2004-10-12 AU AU2004281747A patent/AU2004281747A1/en not_active Abandoned
- 2004-10-12 MX MXPA06004077A patent/MXPA06004077A/es not_active Application Discontinuation
- 2004-10-12 RU RU2006115916/15A patent/RU2006115916A/ru not_active Application Discontinuation
- 2004-10-12 WO PCT/US2004/033739 patent/WO2005037274A1/en not_active Ceased
- 2004-10-12 CA CA002541857A patent/CA2541857A1/en not_active Abandoned
- 2004-10-12 BR BRPI0415249-2A patent/BRPI0415249A/pt not_active Application Discontinuation
-
2006
- 2006-04-09 IL IL174864A patent/IL174864A0/en unknown
- 2006-05-10 NO NO20062104A patent/NO20062104L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| JP2005518433A5 (enExample) | ||
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| FI3782612T3 (fi) | Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi | |
| WO2008047023A3 (fr) | Methode d'immunisation contre les 4 serotypes de la dengue | |
| BRPI0403935A (pt) | Formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
| NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
| EP1261361A4 (en) | ORAL, NASALA AND PULMONAL DOSAGE FORMULATIONS OF COPOLYMERS | |
| MY136136A (en) | Pharmaceutical compositions containing terbinafin and use thereof | |
| WO2009026473A3 (en) | Stabilized therapeutic compositions and formulations | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| MXPA04001933A (es) | Composicion farmaceutica que comprende lumiracoxib. | |
| DE60102590D1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
| JP2004525940A5 (enExample) | ||
| PT1656131E (pt) | Utilização de betaína para tratar claudicação intermitente | |
| UA102111C2 (uk) | Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі | |
| NO20072893L (no) | Fast, peroralt prevensjonsmiddel | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
| JP2006508994A5 (enExample) | ||
| WO2006138317A3 (en) | Dosage regimen for prasugrel | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية |